LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating claims of potential misrepresentations by Avalanche Biotechnologies, Inc. (“Avalanche” or the “Company”) (NASDAQ: AAVL). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased Avalanche shares on or before June 15, 2015, and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us by email at firstname.lastname@example.org or through the firm’s website at http://www.Goldberglawpc.com.
On June 15, 2015, Avalanche held a conference call to discuss their Phase IIa trial results concerning a gene therapy treatment for wet age-related macular degeneration. During the call Avalanche stated that the study was not designed to demonstrate statistically significant differences between the active and control groups. As a result, shares dropped over 56% the following day to end at $17.05 on June 16, 2015.
If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.